June 3, 2008

The stocks in today's report:

The American Society of Clinical Oncology (ASCO) will conclude a 4-day meeting in Chicago on Tuesday where 30,000 Oncologist, Scientists, and Medical Professionals gathered to discuss treatment methods for Cancer Patients going forward.

The conclusions seem to be that there are no new exciting drugs on the Market, but some of the existing drugs have expanding applications. 

I am not a doctor, I do not study Cancer treatments, and I do not specialize in trading Cancer Stocks, but what I do often trumps that subjective analysis.  I study the technical trading patterns of the underlying stocks.  Years ago when DNA broke out, for example, the technical patterns told us that DNA was a clear winner.  Along those same lines, we have reviewed the stocks in this report; maybe one of them are offering important signals as well.  The following objective analysis incorporates all current news and expected news, and it shows the bias of 'Smart Money' in each of these names.  IE our report shows you where Smart Money is buying or selling these stocks respectively.

Novartis (NVS)  Novartis is in the process of testing longer-term resistance according to our analysis.  This is a very important test.  The recent news related to Zometa withstanding, if shares of Novartis fail to move above longer-term levels of resistance as defined in our objective analysis the stock will stall and turn lower.  Traders and investors alike should monitor this longer term resistance level and incorporate that into their analysis.  Understand that fundamental analysis is step one, and hopefully everyone is taking the proper measures to evaluate this company on a fundamental level too, but the technical analysis of this company is truly the only objective analysis available for investment timing purposes because it tells us where smart money is buying the stock; our report does just that.  Our analysis is available exclusively to our members and trial members.  When you read our report for Novartis make sure to pay careful attention to longer-term parameter #3 in our trading report.  This represents longer-term analysis and it should be used  as your inflection parameter.  If Novartis remains below longer-term parameter #3 the stock will decline all the way to longer-term support again as outlined in that report.  However, if longer parameter #1 breaks higher the stock is likely to accelerate aggressively instead.  Click here to review the report and the trading plans we have provided in association with this analysis now: NVS Report

Wyeth (WYE) The good news is that shares of WYE have been fluctuating within a relatively stable trading channel.  The bad news is, the upside catalysts are not immediately aggressive.  The analysis offered in our objective report tells us that the stock has limited upside.  Yes, the stock is currently oscillating higher within a long term trading channel and that indeed is a positive sign, but once resistance is tested the stock is likely to retreat once again according to our analysis.  This puts a cap on the shares of WYE and limits the potential returns from investment into the stock at this time.  We have identified resistance as longer-term parameter #3 and our real-time trading report.  We expect the stock to increase slightly from current models to this resistance parameter and then turning lower again.  Aggressive upside moves are only probable if longer-term resistance breaks higher, and the current patterns in the stock suggests that it will not. Our unbiased analysis of WYE will detail this summary analysis and it is available exclusively to members and trial members.  Click here to access the report and make sure to review longer-term parameter #3 first: WYE Report

Genentech (DNA)   Shares of Genentech recently broke above a longer term inflection point and the stock now appears poised to increase aggressively and test longer-term resistance again.  We have defined longer-term resistance in our objective analysis.  Included in our analysis are news events associated with DNA, trading patterns, and most importantly the underlying sentiment that investors have about the stock.  Our report helps you understand what smart money is doing, how they are investing, and it provides detailed trading plans associated with that analysis.  Currently our analysis tells us to expect shares of Genentech to move higher aggressively and test longer-term parameter #3 as detailed in our report.  However, in order to do that stock must remain above longer-term parameter #2 first.  This is the inflection point that was recently broken and if the stock remains above this level buy signals will exist and our upside target of resistance will remain intact.  However, if it breaks back below longer-term parameter #2 a bearish signal will present itself and declines back to longer term support as defined in our report should be expected instead.  This inflection point, longer-term parameter #2, should be reviewed first when you review our analysis and the plans in our report.  We have made this report available exclusively to our members and trial members.  Click here to review the report: DNA Report

Imclone (IMCL)  After testing a level of longer-term resistance perfectly in April, shares of ImClone are rapidly declining towards longer-term support is again.  According to our objective analysis the downside risk in shares of ImClone currently appear limited.  Slightly lower levels are likely until such time as longer-term support is tested, but once support is tested, assuming that support remains intact, a buy signal will present itself.  We have identified this buy signal as longer-term parameter #1 in our objective trading analysis for ImClone.  We have prepared a report exclusive to members and trial members which outlines strategic trading plans for this stock as well.  Included in our report on all of the recent news events, technical analysis, and the underlying investor sentiment associated with ImClone.  When you review the report make sure to pay careful attention to longer-term parameter #1.  The ability or inability of the stock to remain above this important support level should be the determining fact in the direction of this stock going forward.  Click here to review the report: IMCL Report

Avant (AVAN)  Our objective trading report for AVAN suggests that we should limit our decisions to invest in this company to trading decisions.  In fact, the best way to play this stock according to our objective analysis is to trade AVAN intraday for the time being.  Therefore, for aggressive traders interested in taking advantage of the current volatility in shares of AVAN we have supplied day trading plans for this stock in our report.  The plans tell you where you should enter your trades, either long or short, where your price targets should be, and where your stop losses should be placed.  This objective trading analysis is available exclusively to our members and trial members.  The plans in our real-time trading report are dynamic and they change as the price of the stock fluctuates, so make sure to update this report throughout the day as the stock moves.  Also, remember that opportunities to trade both long and short arise from time to time, and this report will alert you to both.  Click here to access our report: AVAN Report

Acorda (ACOR)  If you are interested in buying ACOR, wait for a slight pullback first.  The stock recently broke out and it now rests above our stated longer-term resistance parameter.  This is a bullish sign, so the bias in the stock is up overall, but this breakout pattern usually results in a slight pullback first, before additional upside is realized.  If you are interested in buying shares of ACOR you should wait for that pullback.  When longer-term resistance broke higher it was converted into a level of longer-term support.  Therefore, we expect the stock to decline to that converted level of support relatively soon and from there buy signals will present themselves again.  In fact, if that converted support level breaks bearish signs may present themselves instead, so that's a good place to incorporate risk controls too.  Chasing the stock from current levels is probably unwise.  Timing is everything when it comes to trading stocks like this and our objective report tells you to be patient.  This report is available to our members and trial members exclusively.  Click here to review the report and pay careful attention to longer-term parameter #3, because this is converted longer-term support: ACOR Report

For details on our Strategic Plan please login or sign up for a free trial.

Good Trading

Stock Traders Daily

http://www.stocktradersdaily.com

1.866.213.2067